<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2587">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127486</url>
  </required_header>
  <id_info>
    <org_study_id>18256</org_study_id>
    <secondary_id>I5Q-MC-CGBD</secondary_id>
    <nct_id>NCT05127486</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine</brief_title>
  <acronym>CHALLENGE-MIG</acronym>
  <official_title>A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the&#xD;
      prevention of migraine in participants with episodic migraine. The study duration will be&#xD;
      approximately 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 50% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with ≥50% reduction from baseline in monthly migraine headache days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 3</time_frame>
    <description>Overall mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 75% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with ≥75% reduction from baseline in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 1 Month</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 2 Months</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean change from baseline in the number of monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</measure>
    <time_frame>Baseline, Month 1 through Month 3</time_frame>
    <description>Overall mean change from baseline in the number of monthly migraine headache days requiring medication for the acute treatment of migraine or headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Role Function-Restrictive (RF-R) Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Role Function-Restrictive (RF-R) domain score of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Monthly Percentage of Participants with a 100% Response Rate</measure>
    <time_frame>Month 1 through Month 3</time_frame>
    <description>The mean monthly percentage of participants will be an average of month 1 through month 3 response percentages where response is defined with 100% reduction from baseline in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in MSQ v2.1 total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Role Function-Preventive (RF-P) Domain Score of Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in RF-P Domain Score of MSQ v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Emotional Function (EF) Domain Score of Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in EF domain score of MSQ v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MIDAS (Migraine Disability Assessment) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in MIDAS total score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Migraine</condition>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered subcutaneously (SC).&#xD;
Placebo for rimegepant will be used for blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rimegepant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rimegepant administered oral disintegrating tablets (ODT).&#xD;
Placebo for galcanezumab will be used for blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered ODT</description>
    <arm_group_label>Galcanezumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimegepant</intervention_name>
    <description>Administered ODT</description>
    <arm_group_label>Rimegepant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Rimegepant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of migraine, with or without aura, as determined by the study&#xD;
             investigator and in consideration of International Headache Society International&#xD;
             Classification of Headache Disorders - 3rd edition guidelines (ICHD-3 2018)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known hypersensitivity to rimegepant or galcanezumab, and their excipients, or&#xD;
             to multiple drugs, monoclonal antibodies or other therapeutic proteins&#xD;
&#xD;
          -  Have acute cardiovascular events and/or serious cardiovascular risk, or have had&#xD;
             myocardial infarction, unstable angina, percutaneous coronary intervention, coronary&#xD;
             artery bypass graft, or stroke within 6 months of screening, or have planned&#xD;
             cardiovascular surgery or percutaneous coronary angioplasty.&#xD;
&#xD;
          -  Evidence of significant active or unstable psychiatric disease by medical history,&#xD;
             such as bipolar disorder, schizophrenia, personality disorders, or other serious mood&#xD;
             or anxiety disorders.&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Current use or prior exposure to any calcitonin gene related peptide (CGRP) antagonist&#xD;
             (small molecule or antibody) for any indication, including those who have previously&#xD;
             completed or withdrawn from this study or any other study investigating a CGRP&#xD;
             antagonist (small molecule or antibody)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gilbert Neurology Partners, PLLC/CCT Research</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-761-9631</phone>
    </contact>
    <investigator>
      <last_name>Jonathan William Hodgson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC Tempe</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-910-3343</phone>
    </contact>
    <investigator>
      <last_name>Corey G Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Banning</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>951-755-0223</phone>
    </contact>
    <investigator>
      <last_name>Judith L. Kirstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research-Chula Vista</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>619-955-5246</phone>
    </contact>
    <investigator>
      <last_name>Michael P Waters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-274-4226</phone>
    </contact>
    <investigator>
      <last_name>Gary K Boone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>949-752-7910</phone>
    </contact>
    <investigator>
      <last_name>Nader Oskooilar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - North Hollywood</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>818-558-7555</phone>
    </contact>
    <investigator>
      <last_name>Teresa S Sligh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9097929007</phone>
    </contact>
    <investigator>
      <last_name>Donald Lee Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark T Leibowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>619-660-9068</phone>
    </contact>
    <investigator>
      <last_name>Hanid Audish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SFM Clinical Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-939-0333</phone>
    </contact>
    <investigator>
      <last_name>Marc Feinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>727-584-6368</phone>
    </contact>
    <investigator>
      <last_name>Miguel Trevino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMR Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3054455637</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Bruce Rosen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research Center, Inc.</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-907-6960</phone>
    </contact>
    <investigator>
      <last_name>Patricia Junquera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites- Clinical Research Unit</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>904-740-0770</phone>
    </contact>
    <investigator>
      <last_name>Bruce G Rankin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-741-2033</phone>
    </contact>
    <investigator>
      <last_name>Ronald Z Surowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-595-4041</phone>
    </contact>
    <investigator>
      <last_name>Victor Faradji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julie Schwartzbard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Consultants</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-694-1010</phone>
    </contact>
    <investigator>
      <last_name>Michael M. Tuchman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-4799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kavita Kalidas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-689-0606</phone>
    </contact>
    <investigator>
      <last_name>Pamela Kane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Better Health Clinical Research</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>770-252-7562</phone>
    </contact>
    <investigator>
      <last_name>Sandeep Vaid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9127904837</phone>
    </contact>
    <investigator>
      <last_name>John Michael Hemphill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8124269576</phone>
    </contact>
    <investigator>
      <last_name>Renee Michelle Galen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>316-600-5127</phone>
    </contact>
    <investigator>
      <last_name>Michael Rausch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>859-264-8999</phone>
    </contact>
    <investigator>
      <last_name>Mark Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>502-515-5672</phone>
    </contact>
    <investigator>
      <last_name>Harold E. Bays</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>504-304-7197</phone>
    </contact>
    <investigator>
      <last_name>Robert Jeanfreau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>504-336-2667</phone>
    </contact>
    <investigator>
      <last_name>Patrick M Dennis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-477-4868</phone>
    </contact>
    <investigator>
      <last_name>Arkadiy Stolyar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Head, Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>734-677-6000</phone>
    </contact>
    <investigator>
      <last_name>Joel R. Saper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcturus Healthcare , PLC, Troy Internal Medicine Research Division</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>248-312-0025</phone>
    </contact>
    <investigator>
      <last_name>Neil J. Fraser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>228-206-1283</phone>
    </contact>
    <investigator>
      <last_name>Paul Matherne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Citizens Memorial Hospital District</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>417-328-7781</phone>
    </contact>
    <investigator>
      <last_name>Curtis P. Schreiber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>702-597-9825</phone>
    </contact>
    <investigator>
      <last_name>Michael B. Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>505-224-7407</phone>
    </contact>
    <investigator>
      <last_name>Marigene Salazar Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>505-243-1627</phone>
    </contact>
    <investigator>
      <last_name>Quito Osuna Carr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center (Research Facility)</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>716-558-5670</phone>
    </contact>
    <investigator>
      <last_name>Shivang G Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-881-0309</phone>
    </contact>
    <investigator>
      <last_name>Craig LaForce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroScience Research Center, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>330-244-2542</phone>
    </contact>
    <investigator>
      <last_name>Ryan Drake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>405-534-5609</phone>
    </contact>
    <investigator>
      <last_name>Kyle W Rickner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>405-701-2466</phone>
    </contact>
    <investigator>
      <last_name>Steven Cox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>405-602-3939</phone>
    </contact>
    <investigator>
      <last_name>Carl P Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>504-336-2667</phone>
    </contact>
    <investigator>
      <last_name>Melita L Tate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>405-594-7712</phone>
    </contact>
    <investigator>
      <last_name>Robert Lockwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Medford</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>512-388-5717</phone>
    </contact>
    <investigator>
      <last_name>Sarah Smiley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8643340141</phone>
    </contact>
    <investigator>
      <last_name>William David Byars</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Neurology Research, P.C.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>608-848-8900</phone>
    </contact>
    <investigator>
      <last_name>Mary D Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>843-856-3784</phone>
    </contact>
    <investigator>
      <last_name>Yvonne Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8653059100 x246</phone>
    </contact>
    <investigator>
      <last_name>William B. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-329-0197</phone>
    </contact>
    <investigator>
      <last_name>STEPHAN C. SHARP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>512-380-9925</phone>
    </contact>
    <investigator>
      <last_name>John D Hudson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ACRC Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-379-2272</phone>
    </contact>
    <investigator>
      <last_name>Matthew Brimberry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ACRC Trials</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-379-2272</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-369-2600</phone>
    </contact>
    <investigator>
      <last_name>Michael J Downing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>817-348-0228</phone>
    </contact>
    <investigator>
      <last_name>Mark A Koch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management, LLC.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>281-240-1045</phone>
    </contact>
    <investigator>
      <last_name>Aramis Cosme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ACRC Trials</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>972-354-1520</phone>
    </contact>
    <investigator>
      <last_name>Madhavi Ampajwala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>801-719-2316</phone>
    </contact>
    <investigator>
      <last_name>Justin Mansfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara Rizzardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC - AMR Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>757-627-7446</phone>
    </contact>
    <investigator>
      <last_name>Mary C Bailey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>757-226-0655</phone>
    </contact>
    <investigator>
      <last_name>Carmen R Fuentes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/muhFfaGNSBYar2xzfLSZR</url>
    <description>A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (CHALLENGE-MIG)</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

